Insilico Medicine listed on the Hong Kong Stock Exchange at the end of 2025, becoming the first AI-driven biotech company to go public in Main Board under Chapter 8.05 listing rules of the HKEX.
This initial public offering (IPO) raised a total of HKD 2.277 billion ($292 million), achieving the largest biotech IPO in Hong Kong this year.
“With this massively oversubscribed listing we set several world’s firsts further confirming Insilico’s validated leadership position in…
